Conference Co-Chairmttc.org/wp-content/uploads/2014/09/Nano2007_Notebook.pdfemerging nanotechnology and microtechnology industry in Massachusetts: from companies just being formed

Welcome to the 3rd Annual Nanotech and Microtech Investors Forum! We are pleased to provide this opportunity for investors, inventors, entrepreneurs and researchers to see a broad range of the

emerging nanotechnology and microtechnology industry in Massachusetts: from companies just being formed to those with several years of progress; from domestic to international opportunities for entrepre-neurs; from the practical applications of these technologies to the most innovative of approaches.

Nanotechnology is being successfully applied to new products that are being widely sold in large quan-tities, from new materials used in domestic consumer goods to reformulated drugs and biocompatible materials used in medical devices. Similarly the use of microtechnology devices is now a part of every-day life, from the air bag accelerometers in your car to the ink jet printer on your desk. According to Lux Research, more than $50 billion in products sales last year incorporated nanotechnology. The sector also continues to attract major venture capital investment, with $699 million in new investments in 2006 – a 10% increase over investments in 2005. The Nanotech and Microtech Investors Forum allows you to see a select group of new technologies that are being actively commercialized by their inventors and will form the basis for new and improved products.

Our mission in organizing this conference is to reveal and promote the most exciting applications of nanotechnology and microtechnology being developed in Massachusetts. Today’s conference features a panel of investors, who are all leaders in their sectors, and who will each talk about their own invest-ment strategies to develop and apply nanotechnologies and microtechnologies. In addition, the program will showcase ten presenting companies and researchers with a history of successful commercial ap-plications of nanotechnology and microtechnology. These presenters will be joined at the Reception by additional posters presenters and exhibitors from MA Institutions who are also featuring new research available for commercialization.

We are particularly grateful to our planning team for their help and support in organizing the 3nd Annual Nanotech and Microtech Investors Forum. We would also like to thank our sponsor, Fish and Richardson, who is as committed as we are to see this industry sector grow.

We hope you will enjoy today’s program and look forward to seeing you among the attendees of this an-nual event in 2008.

Stephen Zamierowski, Conference Co-ChairTech-Venture Center Director, Deloitte

Dr. Abigail A. Barrow, Conference Co-ChairDirector, MTTC

The 3rd Annual Nanotech & Microtech Investors Forum

ii

December 3, 2007Newton Marriott ∙ Newton, MA

iii

Table of ContentsConference Agenda ...................................................................... v

Speaker Biographies ....................................................................7J. Peter Fasse _____________________________________________________ 8

Howard Berke _____________________________________________________ 8

Marc G. Stanley __________________________________________________ 9

Josh Wolfe ________________________________________________________ 9

Sponsor, Affiliate & Hosts ..................................................... 11Sponsor _________________________________________________________ 12

Nonprofit Affiliate _____________________________________________ 13

Hosts ____________________________________________________________ 14

Startup Company Profiles ....................................................... 17About the Investor Pitches ____________________________________ 19

Alenas Imaging LLC _____________________________________________ 21

Aphios Corporation _____________________________________________ 22

Applied NanoWorks, Inc. _______________________________________ 24

Harvard Medical School and Northeastern University _____ 26

IntelliSense Corporation ______________________________________ 27

Northeastern University ______________________________________ 28

Prodyne Corp. ___________________________________________________ 30

University of Massachusetts Lowell _________________________ 32

Vista Therapeutics ______________________________________________ 34

Additional Exhibitors ............................................................... 37Harvard University (tabletop) _________________________________ 37

University of Massachusetts Amherst (tabletop) ____________ 37

University of Massachusetts Lowell (tabletop) _____________ 37

University of Massachusetts Lowell (poster) ________________ 37


iv

v

October 29 & 30, 2007Hynes Convention Center ∙ Boston, MA

CONFERENCE AGENDA

2:00 – 2:30

Registration (Hallway) & Networking and Exhibits (Salon D)

2:30 – 3:30 Salons ABC

Welcome: Abi Barrow, MTTC

Panel:“Current Trends in Investing in the Very Small”

Moderator:J. Peter Fasse, Principal, Fish & Richardson P.C.

Panelists:

Howard Berke, Executive Chairman and co-founder of Konarka Technologies and a member of the leadership team of Good Energies.

Marc G. Stanley, Acting Director of the Technology Innovation Program at the National Institute of Standards and Technology.

Josh Wolfe, Founding Partner & Managing Director, Lux Capital Management.

3:30 – 3:50 Coffee Break (Salon D)

3:50 – 5:30 Salons ABC

Investor Pitches

5:30 – 6:30 Networking Reception & Exhibits (Salon D)


Biographies 7

Speaker BiographiesPanelist Biographies

J. Peter Fasse ....................................................................................................................................8Principal, Fish & Richardson P.C.

Panel Moderator

Howard Berke ....................................................................................................................................8Chairman and co-founder, Konarka Technologies

Senior Advisor, Good Energies

Marc G. Stanley ..............................................................................................................................9Acting Director of the Technology Innovation Program, National Institute of Standards and Technology.

Josh Wolfe ............................................................................................................................................9Founding Partner & Managing Director, Lux Capital Management


� Biographies

Panelist Biographies

J. Peter FassePrincipal, Fish & Richardson P.C.Panel Moderator

Peter Fasse is a Principal in the Boston office of Fish & Richardson P.C. He has over 20 years of experience in various fields including molecular biology, chemistry, nanotechnology, medical imaging, diagnostics, and therapy, optics, and biomechanical and biomedical engineering. Specific applications relate to, e.g., implant-able continuous drug delivery devices and micro/nano-capsules, diagnostic and therapeutic “biochips,” nano-composites, human and bacterial genes and polypeptides, nucleic acid probes, supercritical fluid deposition of semiconductor nanolayers, tissue engineering, near-infrared diagnostic devices, computer-controlled cy-tometers and microscopes, laser ablation and cutting devices, and diagnostic and therapeutic methods for, e.g., cancer, autism, diabetes, and various bacterial and fungal infections.

Education: Massachusetts Institute of Technology B.S. Bioelectrical Engineering, May 1983, and B.S. Life Sciences, December 1983; George Washington University J.D. 1987

Howard BerkeChairman and co-founder, Konarka Technologies Senior Advisor, Good Energies

Howard Berke is a Senior Advisor to Good Energies, a private investment firm in solar photovoltaic compa-nies and wind developers. Good Energies contributes as a strategic investor to the ongoing energy transition process through its long-term investments and its support of development initiatives in the field of clean en-ergy technologies. Good Energies is a member of COFRA Holding AG, Zug/Switzerland and is represented through offices in London, New York, Toronto, Washington DC and Zug (www.goodenergies.com)

Mr. Berke has nearly 30 years of hands-on management experience launching, building and leading both public and private technology companies. This includes over 20 years of general management with full P&L responsibility for eight start-up companies and ten years of business development and marketing focusing on emerging technologies. Howard Berke is currently chairman and co-founder of Konarka Technologies, an in-novator in development and commercialization of Power Plastic™, a material that converts light to energy.

He has founded or co-founded 13 start-up companies and has initiated and completed numerous corporate acquisitions, mergers and R&D joint ventures in the U.S., Europe and Asia. He advises start-up companies and entrepreneurs in a wide range of fields including medical devices, biotech informatics, software, net-working, telecom and energy technology.

In addition to serving as delegate to the World Economic Forum’s Technology Pioneers, he sits on the board of directors for ACORE, has helped to found and organize the New England Clean Energy Council and has guest lectured on entrepreneurship at Yale, Harvard, MIT and elsewhere throughout the world.

Berke received a Master of Business Administration (MBA) from the University of Chicago and a Bachelor of Arts (BA) from Yale University. His academic training includes finance, accounting, operations research, corporate law, architecture and physics.


Biographies 9

Marc G. StanleyActing Director of the Technology Innovation Program, National Institute of Standards and Technology.

On September 10, 2007, Mr. Marc G. Stanley was appointed Acting Director of the Technology Innovation Program (TIP) at the National Institute of Standards and Technology (NIST) and has been the Director of the Advanced Technology Program (ATP) since June 2003. He also serves as a U.S. Governor on the Is-rael - U.S. Binational Industrial Research and Development (BIRD) Foundation Board of Governors and as the American Director on the Trilateral Industrial Development (TRIDE) Executive Committee. Mr. Stanley served as the Acting Director of ATP from 2001 to 2003 and as the Associate Director for ATP from 1993 to 2001. Before coming to NIST, Mr. Stanley was the Associate Deputy Secretary of the U.S. Department of Commerce (DoC) by Presidential appointment. He served as Counselor to the NIST Director, as a consul-tant to DoC’s Technology Administration, and as Assistant Secretary for Congressional and Intergovernmen-tal Affairs at DoC.

Mr. Stanley earned a BA from George Washington University and a Bachelor of Law degree from the Uni-versity of Baltimore.

Josh WolfeFounding Partner & Managing Director, Lux Capital Management

Josh Wolfe is a co-founder and Managing Partner of Lux Capital focusing on the firms’ venture investments in physical & life sciences. He has led Lux’s direct investments in Nanosys, Molecular Imprints, Cambrios, Crystal IS, Silicon Clocks and Magen. Josh sits on the Board of Crystal IS, Silicon Clocks, Lux Research (a research and advisory firm serving Fortune 100, government and buy-side clients) and Angstrom Publishing (a media joint venture with Forbes, Inc.).

Before forming Lux Capital, he worked in Salomon Smith Barney’s Investment Banking group , Merrill Lynch’s Financial Futures Options/Government Strategy Group and Prudential Securities Municipal Finance depart-ment. Josh serves on Merrill Lynch’s TechBrains Advisory Board. Josh was a Westinghouse semi-finalist at 15 and conducted and published cutting edge HIV/AIDS and immunopathology research. He has been pub-lished in Nature Biotechnology, Cell Vision and The Journal of Leukocyte Biology, leading medical/immunol-ogy journals. Josh graduated with distinction from Cornell University with a B.S. in Economics and Finance.

Josh has a column at Forbes magazine, is the author of the 500 pg book “The Nanotech Report” and Editor of Forbes’ fastest growing monthly investment publication, the “Forbes/Wolfe Emerging Tech Report.” His public policy work includes co-founding the NanoBusiness Alliance - the industry organization for nanotech-nology and joined President Bush in the Oval Office during the historic signing of the 21st Century Nanotech R&D Act in December 2003. He has been an invited kenyote or guest lecturer at over 300 events includ-ing Harvard Business School, Yale, Columbia, Cornell, Wharton, the National Science Foundation, FDA and government officials in France, Spain, Germany, Canada, Brazil, UK and Singapore. Red Herring has called him “Mr. Nano”. Steve Forbes has called Lux a “powerhouse of nanotech brainpower” and Josh Wolfe “America’s Leading Authority on Nanotechnology”. Josh was honored by Crain’s magazine as one of their “40 under 40” and has appeared in Business Week, The New York Times, Forbes, The Wall Street Journal, Wired, CBS News, The New York Post and has been a regular guest on CNBC’s Kudlow & Cramer, Bullseye and Closing Bell.He is a founding member of junior boards for The East Harlem School at Exodus House, the Hospital for Special Surgery, Coney Island Prep and the Cancer Research Institute. Josh is a native of Brooklyn, New York.


10 Sponsors & Hosts


Sponsors & Hosts 11

Sponsor, Affiliate & HostsSponsor ................................................................................................................................................12

Fish & Richardson

Nonprofit Affiliate ..................................................................................................................13NSTI

Hosts .......................................................................................................................................................14The Massachusetts Technology Transfer Center

Deloitte


12 Sponsors & Hosts

Sponsor

A national law firm with more than 500 lawyers in 11 offices, Fish & Richardson P.C. is one of the largest firms practicing intellectual property, litigation, and corporate law – and we’re the only firm with a truly national intellectual property practice. Founded in 1878, the firm represented Thomas Edison, Alexander Graham Bell, and the Wright Brothers. For more than 125 years we have served great innovators, helping to protect countless ideas, nurture discoveries, and bring new concepts to market. The firm prosecuted and litigated many of the fundamental patents of an industrialized America, serving corporations creating the cutting-edge technologies of the day: the telephone, the air-brake, the steam turbine, the automobile, and the radio. Frederick Fish, the firm’s founder, was for many years the acknowledged leader of the patent bar of the entire country at a time when patents were more important than they had ever been. Today, we continue to represent the great innovators of our time.

The biggest Fish in the sea has grown Fish opened its first international office in Munich, Germany, in October 2007. The office opened with five professionals, including two partners from the Bardehle Pagenberg firm, with plans to grow to twelve professionals by the end of 2008.

Fish was named the top intellectual property law firm in the country in Corporate Counsel Magazine’s sixth annual survey of “Who Represents America’s Biggest Companies.” Corporate Counsel looked at which law firms Fortune 250 corporations used the most in four key areas: commercial law and contracts litigation, corporate transactions, employment and labor litigation, and IP litigation and patent prosecution. We took the top spot for IP litigation and patent prosecution. Twenty-three Fish attorneys from eight offices were named in the 2008 edition of The Best Lawyers in America. Fish was also ranked number one in the United States in Intellectual Property Law with 19 attorneys; number one in Massachusetts in Intellectual Property Law with eight attorneys; and number one in Boston, MA, in Intellectual Property Law, with eight attorneys. IP Law360 announced Fish at the top of the ranks in patent litigation and trademark cases (February 2007). We once again topped the annual list of patent litigation practices in the United States at number one with 89 new cases in 2006. We also handle more patent litigation than any other firm and we’re the top firm for patent litigation at the International Trade Commission (IP Law & Business, July and September 2005). Our litigation victories have been on the National Law Journal’s biggest winners lists for four straight years.

Attorneys at Fish help their clients capture the value of their intellectual property through patent, trademark, copyright, and trade secret protection. We file 5,000 patent applications each year and process more than 1,600 patents, making us one of the top firms in the country in number of patents obtained each year. Our staff includes more than 80 PhD’s and 230 of our attorneys are admitted to the patent bar. Fish also wrote and prosecuted the patents on an invention that earned our client recognition as 2003 Inventor of the Year, awarded by the Intellectual Property Owners association. In addition to our intellectual property practice, we have a broad complex litigation practice that includes not only patent, trademark, copyright, and trade secret litigation, but also a wide range of high-stakes, high-tech business litigation. Our regulatory group advises clients seeking to market products subject to FCC and FDA regulation. Our Corporate and Securities Section helps clients with capital structuring and financing, public equity and debt offerings, and a wide range of corporate transactions.

www.fr.com [email protected]

800-818-5070


Sponsors & Hosts 13

Nonprofit Affiliate

NSTI Nanotech 2008 is the world’s largest and most com-prehensive technical and business event in nanotechnology

More Than 20 Technical Tracks Are Accepting Papers For Conference Consideration, Including the Merck Corporate

Symposium - An Exclusive Program to Nanotech 2008

The submission deadline is December 6th, 2007. Please visit the conference home page to submit an Abstract, and

learn more about the upcoming Nanotech program June 1-5, 2008:

http://www.nsti.org/Nanotech2008/

Nano Science and Technology Institute – One Kendall Square, PMB 308

Cambridge, MA 02139 USA [email protected]


14 Sponsors & Hosts

The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its goal is to support technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachu-setts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

___________________________________________________________________________________

The Center: facilitates and accelerates technology transfer between research institutions and Massa-chusetts companies;promotes collaboration between research institutions and the Commonwealth’s technology industry; assists in the growth of Massachusetts companies, including startups, by enhancing tech-nological leadership; andsupports regional and statewide economic development priorities.

___________________________________________________________________________________

The Center supports the commercialization of research technologies through a variety of programs:

The Center provides mentoring to researchers who believe they have a technology that could serve as the basis of a new company. The process includes the development of a business presentation for an expert board of external reviewers.

Commercialization and Entrepreneurial Education seminars and workshops enable researchers to under-stand the process of commercializing technologies.

Expert technology reviews provide opportunities for Massachusetts research institutes to have external industry experts evaluate technologies and give advice regarding their commercial potential.

Technology Forums allow investors and potential corporate partners to meet with companies formed around technologies developed in Massachusetts research institutes.

Mini-grants support technology development. The Center awards up to $40,000 to inventors from Mas-sachusetts research institutions to fund proof-of-concept research or the development of more refined marketing and commercialization plans.

www.MaTTCenter.org

[email protected]

www.MassTechPortal.org

•

•

•

•


Sponsors & Hosts 15

We connect growing nanotech companies to the best in

professional services Our Technology & Life Sciences practice serves leading technology, biotechnology, and medical device/product companies throughout New England and the world. Our practitioners provide solutions to the wide range of issues that growing companies face throughout their life cycle, from early-stage research companies to global leaders. At our Tech-Venture Center we leverage our intellectual capital, our knowledge, and our experience in the industry to help our early-stage technology and life sciences clients meet their strategic objectives with an approach tailored to the unique needs of a growing company.

For additional information about Deloitte and its Tech-Venture Center, contact:

Steve ZamierowskiDirector, Tech-Venture Center Deloitte & Touche LLP 1000 Winter Street Waltham, MA 02451 USA Phone 617 437 2803 [email protected]

Audit. Tax. Consulting. Financial Advisory

www.deloitte.com/us/tvc

Member of Deloitte Touche Tohmatsu Copyright © 2006 Deloitte Development LLC. All rights reserved


16 Sponsors & Hosts

Startup Companies 17


Startup Company ProfilesAbout the Investor Pitches ..........................................................................................19

Alenas Imaging LLC .................................................................................................................21Dr. Lawrence Domash, President

Aphios Corporation ................................................................................................................22Dr. Trevor P. Castor, President and CEO

Applied NanoWorks, Inc. ...................................................................................................24Eric Burnett, President & CEO

Harvard Medical School and Northeastern University ............26Dale Larson, Director

IntelliSense Corporation................................................................................................27Sandeep Akkaraju, CEO

Northeastern University .................................................................................................28Vladimir Torchilin, Professor and Chair

Prodyne Corp. ...............................................................................................................................30Steven Africk, President

University of Massachusetts Lowell ................................................................32Joey Mead, Professor

Vista Therapeutics ....................................................................................................................34Spencer Bryant Farr, CEO

1� Startup Companies




About the Investor Pitches

Introduction

The Massachusetts Technology Transfer Center hosts several conferences a year, each to showcase early stage entrepreneurs in a different technology or industry sector. The heart of each showcase is the ten-minute investor pitches given by the selected entrepreneurs followed by a reception in an exhibit hall at which interested attendees can meet the entrepreneurs and network with the other participants.

The pool of applicants to present has grown rapidly since our inaugural conference in 2005, so we have selected as broad a range as possible, from technologies still in the university laboratory through to com-panies starting to sell product; from the most polished and experienced presenters to those who have never presented to the business community before; from the most cutting edge technology to more mun-dane processes that still support an innovative business model.

Business and Technology Maturity

The mandate of the MTTC is to help entrepreneurs based in nonprofit research institutions to commercial-ize their technologies. Thus, we always give priority to applicants from our universities. However, we are also working toward economic development in the state, so we in addition welcome entrepreneurs already working in startup companies, giving preference to those who are licensing university technology. You will hear investor pitches from full-time professors and from managers who have been commercializing technologies for thirty years or more.

Some presenters are alumni of our prior conferences; however, they are invited to participate only if they have significant business updates to incorporate into their investor presentation.

We hope that you will find interesting investment and business opportunities amongst our presenters. And please remember that universities and research institutions have significant capabilities in these technical fields, so if you don’t find what you are looking for please ask us and we will try to identify the right institu-tions and researchers to help you.

20 Startup Companies




Alenas Imaging LLCPresented by:Dr. Lawrence Domash, President

Company Overview

Alenas Imaging LLC, a spinoff from Mt. Holyoke College in South Hadley, Massachusetts, was established in September, 2007, to commercialize advanced techniques of thermal imaging created by researchers at Mt. Holyoke and MIT. Alenas technology - which may be described as “thermal imaging without infrared” - will offer temperature visualization solutions for industrial inspection and manufacturing applications with much higher resolutions and much lower costs than existing methods.

The company has three co-founders. Dr. Janice Hudgings is Prof. of Physics at Mt. Holyoke College; she holds a Ph.D. from the University of California, Berkeley. Dr. Rajeev Ram is Prof. of Electrical Engineer-ing at MIT, where he is Director of the Center for Integrated Photonic Systems and Associate Director of the Research Laboratory of Elec-tronics; he holds a Ph.D. from the University of California, Santa Bar-bara. Dr. Lawrence Domash, a consultant to optical technology com-panies, formerly served as Chief Scientist of Aegis Lightwave; he has a Ph.D. in physics from Princeton University.

Product/ Technology Profile

Thermal imaging, which visualizes temperature distributions, is a growing worldwide industry but acceptance has been limited by the high cost and low resolution of existing infrared methods. Today’s best thermal cameras typically cost $75K but may have only 320 X 320 pixels. It has generally been assumed that future opportunities lie in newer infrared sensor technologies.

Alenas Imaging LLC takes a radically different approach - thermal imaging without infrared. Alenas will re-place infrared sensors with ordinary visible light digital cameras combined with sophisticated computational algorithms to capture temperature changes as small as 0.01°C for a wide range of industrial inspection appli-cations. The technology of thermoreflectance imaging as developed in the laboratories of J. Hudgings at Mt. Holyoke College and R. Ram at MIT has made it possible to produce highly sensitive thermal images with up to 2000 X 2000 pixels. Projected system costs are less than 1/5 those of conventional thermal cameras.

Thermoreflectance in the past has mostly been a little known scientific technique. Alenas’ approach will enable it to compete in the $3B non-destructive inspection / evaluation (NDI/NDE) portion of the market for non-realtime imaging, allowing temperature scanning to be applied in manufacturing of electronics and solar cells, maintenance of aircraft and civil structures, and other industrial applications where high resolution and low cost are the keys to wide deployment.

The initial business plan of Alenas is in two stages. Currently the company is filing SBIR / STTR proposals to government agencies; these contracts will fund Alenas to demonstrate novel applications, develop intel-lectual property, and form relationships with future customers and partners. Alenas has received interest from several large US and international companies. When the technology and a precise market focus have been proven, Alenas plans to seek venture investment or a strategic partnership.

Officers and Directors

Dr. Janice Hudgings, CTO Dr. Rajeev Ram, Chief ScientistDr. Lawrence Domash, President

Contact Information

PO Box 612Conway, MA 01341Phone: 413 369 4497 Fax: 413 369 [email protected]



Aphios CorporationPresented by:Dr. Trevor P. Castor, President and CEO

Company Overview

Aphios Corporation (www.aphios.com) is developing enabling technol-ogy platforms for improving the discovery, manufacturing, delivery and pathogenic safety of therapeutic drugs. Argentum Medica, a spin-off from Aphios, is a nanotechnology company focused on developing oral bioavailable therapeutic peptides and proteins.

Argentum Medica business strategy is to establish Phase I/II clinical evidence for the oral delivery of peptides such as biosynthetic insulin or salmon calcitonin followed by Phase I/II clinical evidence for larger protein molecules such as erythroproietin [EPO] and interferon alpha. Subsequently, these products will be out-licensed to multinational phar-maceutical and biotechnology companies for conducting Phase III clini-cal trials and commercialization. In parallel, we will establish collabo-rations with pharmaceutical and biotechnology companies to research and develop orally bioavailable peptides and proteins.

Dr. Trevor P. Castor, President and CEO has about 30 years of diversified business experience rang-ing from management and marketing to technology and business development in the energy, chemi-cal and biopharmaceutical industries. Mr. Jerry Goldberg, Vice President, Marketing & Sales, has more than 18 years experience in market-ing and selling high technology products.Mr. Joseph F. Faris, CPA, Chief Financial Officer, has previously worked with Hemagen Diagnostics, Medical Research, T Cell Sciences and Neurogen, Inc.


SCIENTIFIC STRATEGY

Argentum plans to enhance the oral bioavailability of therapeutic proteins by encapsulating protein nanoparti-cles in biodegradable polymer nanospheres. Nanoencapsulation will be used to protect the protein nanopar-ticles during the stomach passage; the residence time in the stomach will be short compared to the protein release rate from the polymer nanospheres. We believe that our oral delivery nanotechnology will be ap-plicable to large as well small protein molecules since we have demonstrated that our protein nanoparticles technology is independent of size and molecular weight (MW).

INTELLECTUAL PROPERTY STRATEGY

Exclusively license enabling nanotechnology platforms and patents from Aphios for oral delivery of proteins and peptides:

“Method and Size Reduction of Proteins” U.S. Patent No. 6,051, 694, April 18, 2000“Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein” U.S. Patent No. 7,147,806 B2, Dec. 12, 2006

Generate novel products and technologies that will be owned by Argentum Medica.

•

•

•

••

Officers and Directors

Dr. Trevor P. Castor, President and CEO, ChairmanMs. Carole W. Tomko, DirectorMr. Anthony Janiuk, Director

Contact Information

3-E Gill StreetWoburn, MA 01801Phone: (781) 932-6933Fax: (781) [email protected]: www.aphios.com



Market Opportunity and Size:

With completion of the human genome sequence, the growth of the biotechnology marketplace is expanding rapidly. One of the major factors limiting the marketability and industrialization of biotechnology drugs is the method of delivery. These macromolecules are usually very effective when they can get to the disease site. They are also, for the most part, nontoxic since they mostly mimic human proteins. Unfortunately, these molecules, like insulin, are quite large and are most readily delivered by daily injections or intravenously in a hospital setting.

The drug delivery market was approximately $20 billion in 1995 and grew to $70 billion in 2005. It is pres-ently characterized by rapid technology development and new technology adoption due to the demand for new delivery formats capable of delivering difficult-to-administer small pharmaceutical molecules and bio-technology drugs (protein macromolecules). For example, an oral calcitonin product is estimated to gener-ate revenues in the range of $1.0 to 1.5 billion. Approximately 20.8 million people in the United States have diabetes, an estimated 14.6 million are diagnosed and 6.2 million are undiagnosed. The estimated market size for insulin is $5 billion worldwide.

Competition:

While the oral delivery of proteins and peptides are challenging because of enzymatic degradation in the GI tract and absorption through epithelial cells, oral administration is still more attractive in terms of ease of use and patient compliance. Consequently, there are numerous companies developing different oral delivery technologies for peptides.

The leading company in this field is Emisphere Technologies Inc., Tarrytown, NJ, that utilizes custom-de-signed synthetic carrier molecules to transport peptides through membranes in the GI tract. Emisphere is developing five peptides for oral delivery including heparin (Phase III), insulin (Phase II), salmon calcitonin (Phase II), recombinant human growth hormone (Phase I), and the weight-loss associated hormone PYY (Preclinical).

Competitive Advantage:

Argentum technology utilizes SuperFluids TM that avoid the utilization of organic solvents that could dena-ture and reduce/eliminate the integrity of proteins and peptides. Most all the competition has focused on the oral delivery of low MW peptides such as biosynthetic insulin (~ 5 KD) and salmon calcitonin (~ 3 KD), and not on the oral delivery of high MW proteins such as erythroproietin (~ 30 KD) and interferon alpha (> 100 KD).

Future Financial Plans

Argentum Medica is raising a Series A round of $8 million to establish POC and IND-enabling data for an orally bioavailable peptide in a two year period. Within 12 months of the Series A raise, Argentum plans to initiate the establishment of $15 million to conduct Phase I and II clinical trials.



Applied NanoWorks, Inc.Presented by:Eric Burnett, President & CEO

Company Overview

Applied NanoWorks (ANW) has developed a new, patent pending man-ufacturing process that very cost effectively makes nano-materials that enable higher performance in material systems and devices that utilize metal and metal oxide thin films and additives. Based in the Albany, NY area, the company’s Molecular Control Platform (MCP) uses chemical “handles” to improve material compatibility and manufacturability for its precursors and nano-particles that readily integrate into a broad range of manufacturing materials such as plastics and composite materials. ANW’s products address over $1B in addressable markets and the company is rapidly increasing its production capacity to metric tons per month. Applied NanoWorks’ vision is to become the first 21st century materials company to achieve a $250MM valuation from material and application sales. The management team brings experienced leader-ship at all levels; as CEO, ANW is Eric Burnett’s third technology start-up. Its CTO, Dr. Partha Dutta received NSF’s Young Career Award for his crystal growth and device work at Rensselaer Polytechnic Institute (RPI). Dr. Kyle Litz was a member of GE Global Research’s Innovation Team and a member of several due diligence teams. Mark Rossetti brings continuous processing manufacturing scale-up experience from GE Silicones.


MCP is a manufacturing platform that delivers a new, more flexible and greener metal and metal-oxide pre-cursor than existing alternatives. The traditional approach to integrating metals into organic material sys-tems, metal alkoxides, are insoluble in water, cause excessive corrosion in manufacturing equipment due to lingering salts and are a challenge for many material systems due to both the salts and excessive shrinkage. ANW’s MCP solves all of those problems using a very efficient process. Metal compounds of titanium, zinc, hafnium, copper, silver and zirconium are just some of the metal systems developed to date. Many of these metal precursors are novel molecules (patent pending) which globally impact thousands of existing patents.

Markets and Applications

ANW is focusing on two markets: one to drive immediate revenue and the other a higher value application. In one form, these metal precursors act as excellent strengtheners for reinforced plastics and composite material systems. In the US alone, over 4.2B pounds of reinforced materials are made annually making this an estimated $500MM addressable market for ANW. The second application area is nano-scale coatings, layers and thin film market which is a $275MM market today, nearly tripling to $775MM in the next five years. The electronics industry represents nearly 50% of this market and ANW’s product attributes of water solubil-ity, salt-free and reduced shrinkage are all valued attributes.

Commercial Opportunity

ANW is already conducting a direct sales campaign and has its materials into evaluations at over 30 major manufacturers including BASF, Arkema, Ashland, Dow and many others. In the nano-additives market, ANW is targeting the largest distributors as a mechanism to leverage their distribution channels quickly. In

Officers and Directors:

Eric Burnett, President Partha Dutta

Contact Information:

9 University PlaceRensselaer, NY 12144Phone: 518-471-5780 X402Fax:[email protected]



the electro-less plating markets, ANW is targeting equipment manufacturers and selected end-users due to the strategic and enabling value of its materials. ANW estimates that 90% of both markets are controlled by fewer than 100 identified manufacturers.

Competitive advantage

Simply, the MCP process delivers better performance at a lower manufacturing cost. ANW’s approach how-ever will be to focus on higher value applications where margins can be maximized. In the glass reinforced plastic and composite markets, an estimated net $0.15 per pound cost improves strength up to 50%. In fiber glass and carbon-fiber systems for instance, these improvements are significant and allow them to expand market share against traditional metal parts. In the electro-less plating markets of high performance elec-tronics, ANW’s material attributes (salt-free, water soluble, lower shrinkage) represent a significant reduc-tion in capital and manufacturing costs, improved throughput and higher yield compared to current material systems.


ANW is planning its Series B round of funding in late 2008 to expand its sales efforts and increase manu-facturing capacity. This round is expected to be between $5MM and $10MM, a portion of which will be com-pleted using more traditional funding mechanisms. With an addressable market of over $2B, ANW projects that its sales will increase to over $20MM by 2011.



Harvard Medical School and Northeastern University

Presented by:Dale Larson, Director


The study of binding interactions is a central aspect of basic biology research and pharmaceutical R&D and there are numerous analyti-cal methods available to study various aspects of these interactions. Each has its own strengths and weaknesses. Calorimetry is currently used as a tool to understand a specific reaction and is very important in the study of binding interactions. A calorimeter measures the energy released or absorbed by a reaction over a range of reactant concen-trations to determine the relative contributions of enthalpically driven processes (related to the number and types of bonds) and entropically driven processes (related to the shapes of the binding site and the ligand). Unfortunately, the need for a large amount of protein (0.5 to 5mg) limits its usage. Additionally, there are some reactions where the amount of heat is too small for the current generation of calorimeters to measure.

We are developing a chip scale calorimeter based on extraordinary optical transmission (EOT) through an array of nanometric apertures. Stark et al and Brolo et al have shown that these nanohole array de-vices can be used as affinity sensors where one of the binding partners is immobilized on the surface of the nanohole array device. With these nanohole array sensors the signal is temperature dependent due to the di-electric function of the buffer changing the plasmon excitation conditions. Holding the concentration constant in an approximately 100nm thick layer of dielectric directly above the nanohole array surface enables the use of EOT as a fast and sensitive temperature sensor to measure the heat of reaction (enthalpy, ΔH) from bind-ing events. The inherent ability to multiplex many nanohole array sensor devices on a single chip enables the simultaneous measurement of controls to characterize confounding effects (e.g. buffer dilution, mixing, presence of DMSO in the buffer) and deconvolution of these effects to determine the true heat of reaction.

Early results indicate that a nanohole array calorimetry system has the potential to reduce the amount of protein required by 1000-fold and increase sensitivity by 100-fold. This will expand the use of calorimetry in pharmaceutical R&D and has the potential to become a high-throughput screening tool. With these applica-tions there are recurring sales of the calorimeter chips as well as a capital equipment component.


We are looking for sponsored research combined with a license to develop prototype instrumentation and conduct performance testing.


Dale Larson, Harvard Medical School Greg Kowalski, Northeastern University


Harvard Medical School240 Longwood Avenue, BCMPBoston, MA 02115Phone: 617-432-6171Fax: [email protected]



IntelliSense CorporationPresented by:Sandeep Akkaraju, CEO

Company Overview

Rated by R&D magazine as a top 25 Micro/Nano supplier and by Frost and Sullivan as the Enabling Technology of 2006, IntelliSense is a pri-vately held, profitable Micro/Nano technology. IntelliSense focuses on product breakthroughs based upon micro/nano technology.

IntelliSense’s founders were previously involved in bootstrapping a company and its eventual sale to Corning at $750 million without any external funding.


IntelliSense is working to commercialize three MEMS based products (i)high precision optical instrumentation (ii)inertial devices on a chip and (iii) CAD/EDA products for Micro/Nano.

Market and Application

The optical portfolio is targeted in the space of metrology and lithography and spectroscopy markets with a US TAM of $1.5B, the inertial devices are targeted in the space of GPS replacement, dead reckoning with a TAM of $4 B.


IntelliSense is working closely with commercial partners in the commercialization of the technology

Competitive Advantage

Patents and trade secrets. Unique advantages in terms of cost and performance.


Funds to increase profitability, fuel product development and increase scope of company.


Sandeep Akkaraju, CEO


600 W Cummings Park,Suite 2000Woburn MA 01801Phone: 781 933 8098Fax: 781 933 [email protected]

IntelliSense

2� Startup Companies


Northeastern UniversityPresented by:Vladimir Torchilin, Professor and Chair


Technology Title:

Sonic LbL Technology for Improved Drug Solubilization and Targeted Delivery

We present a breakthrough Sonic Layer-by-Layer nanotechnology (Sonic LbL) that offers novel approach to solubilization and targeted delivery of water-insoluble pharmaceutical compounds, and addresses a multi-billion dollar drug market, including anticancer drug market.

Low solubility in water is an intrinsic property of many drugs, includ-ing powerful anticancer agents. Thus, the market for drug formulation and drug delivery is large and highly competitive. According to Frost & Sullivan (www.frostandsullivan.com) there are currently about 120 companies in the U.S. dealing with drug delivery technology, including pharmaceutical companies, biotechnology companies and small drug delivery companies. Many of those companies focus on drug delivery technologies based on nanobiotechnology and pharmaceutical nano-carriers, such as solid nanoparticles, nanoemulsions, micelles, and liposomes. About 15 nanobiotechnology drug delivery products have been FDA approved, about 30 more are in research and development and approximately 10 are expected to be launched by 2011. Many of these products include poorly soluble substances as an active drug, and the use of various micelles as pharmaceutical nanocarriers represents the most commonly used platform. However, there exists a set of serious problems associated with micel-lar carriers, including low loading efficacy of the drug into the micelles (usually well below 5% by weight); the impossibility to use the same protocol for making solubilized forms of different drugs since each drug requires its own specific conditions for solubilization; problems with controlling the release rate of the drug from micelles; difficulties with the scaling up the technology; insufficient storage stability of micelles and their frequent instability in the body, to name just a few.

Our technology is potentially significantly superior to any other existing technologies, because it not only al-lows for the preparation of stable and bioavailable nanocolloidal dosage forms of poorly soluble drugs, but it also allows for preparing such dosage forms with the controlled drug release rate. Traditional LbL tech-nology allows to assemble polyelectrolyte multilayer shells on various size particles, including those on na-noscale based on an alternate adsorption of oppositely charged polyelectrolytes onto certain surfaces. We developed a novel version of the LbL technology, called Sonic LbL, to make aqueous stable nanocolloids of poorly soluble drugs with high stability, and very high content of the active drug (more than 90% by weight.) In addition, drug release rate from nanocolloids particles can be easily controlled, and various functions, such as specific targeting agents, can be easily attached to the surface of the LbL particles.

Overall, we aim to bring to life a new set of nanocolloidal drug carriers with controlled in vivo properties, which can be prepared with desired stability, loading efficiency, clearance rate, targetability and biodistribu-tion suitable for delivery of poorly soluble pharmaceuticals in a desirable fashion to generate an efficient treatment of a broad variety of tumors in different therapeutic modalities.


Vladimir Torchilin, Professor and Chair


Northeastern University Bouve College of Health Science School of Pharmacy, Department of Pharmaceutical Sciences360 Huntington Avenue, Mugar Building 312Boston, MA 02115Phone: 617-373-3206Fax: [email protected]




The laboratory of Dr. Torchilin will focus on further characterization of Sonic LbL nanocarriers in vitro and in vivo, including study of the properties of LbL-drug nanocolloids and optimization of their stability and drug release rate; testing of the interaction of LbL-drug nanocolloids with cancer cells, their uptake by cells and intracellular fate and the efficacy/cytotoxicity of selected formulations against selected types of cancer.

In parallel, Dr. Torchilin and Northeastern University are developing a business plan for a start up company based on Sonic LbL technology with the focus on anti-cancer therapeutic area, and aggressively seeks li-censing opportunities in other areas.



Prodyne Corp.Presented by: Steven Africk, President

Company Overview

Prodyne is developing Ultrasonic Pulsed Doppler (USPD) methodol-ogy, a novel means to characterize suspensions of particles as small as sub-10-nm. This technique can measure particle concentration, size and physical properties (e.g. compressibility). Measurement of changes in these properties will support monitoring of particle function-alization. For example, changes in particle compressibility can be used to monitor uptake of ‘cargo’ into particles as in drug delivery. Unique properties of the system include single-transducer operation, applica-bility to high concentration samples without dilution and very high reso-lution particle sizing. Products being defined include instrumentation for R&D, quality assurance, and quality control in batch or continuing process (manufacturing) modes. Single-transducer operation will al-low simple incorporation of the system into existing processing ves-sels. The company’s vision is to provide a mix of product sales, custom applications and licensing. Principals have over 70 years experience in acoustics, corporate start ups and management.


The USPD system uses a single transducer to interrogate and receive backscatter from suspensions of mov-ing particles as small as sub-10-nm. The particles may be set into motion by stirring, by their motion exiting a processing step, or by the ‘streaming’ effect due to the interrogating signal itself. The backscatter power spectrum extends over a range of frequencies due to the Doppler effect, which provides a large dynamic range as there is no clutter or environmental noise at the shifted frequencies. The magnitude of the back-scatter is a measure of the concentration and the particle compressibility and/or density and the frequency of spectral peaks measures particle size.


The potential markets for this include R&D and quality and process control in what we call the ‘hard’ particle market (e.g. semiconductors, pigments, CNT’s , printer inks, colloids) and the ‘soft’ markets including bio-technology, pharmacology and medicine. The monitoring and testing equipment industry supporting this market is today is a $20B+ per annum industry, featuring major companies such as Agilent ($5B rev, $15B Mkt Cap), Thermo-Fisher ($7B rev., $22B Mkt Cap), as well as many smaller ones.


Steven Africk, PresidentFred Kern, V.P


30 Fenwick RoadWaban, MA, 02468Phone: 617-699-1258Fax: [email protected]




The target customers in this initial phase include:

• Chemicals and specialty chemicals: Cabot (ink), Dow, DuPont

• Paints & Pigmentation: Sherman-Williams, Benjamin Moore, Glidden

• Semiconductor foundries and equipment manufacturing: Intel, STMicro, TSMC, Applied Materials, Charter, Analog Devices, Jazz

• Nanotechnology: Nantero, Nanolab, Dendritic Nanotechnologies, and others

A number of target customers have confirmed the need for a technology such as ours and have expressed interest. We will market to these groups by networking employing the services of an MIT-trained MBA with strong contacts within these industries. We shall make presentations at technical and industry meetings. We have identified a potential beta customer with whom we have worked in the past to provide a manufac-turing solution based on USPD.

We are also working with instrumentation companies to develop joint scientific programs with the technology and to explore its potential licensing by them.


The USPD system has the following unique properties:

o Single sensor operation and the ability to be incorporated into existing facilities. This supports low cost and highly flexibly applications for process control applications.

o Operations over a large range of concentrations and opaque solutions, eliminating the dilution require-ments typical of optical instruments.

o The ability to measure particle mechanical properties that optical systems cannot.

o The potential for high resolution particle sizing (around 30% vs. factors of 2 or 3 for dynamic light scatter-ing).

o Low cost. Prototypes will cost on the order of $10K.

o Operation down to the sub-ten-nanometer range.

o Two patents pending.

o We will continue system development through research at MIT.


We are seeking an investment of $750K – 1M for a two-year development program to:

o Complete the technical development of and fully characterize the system.

o Demonstrate prototypes using fully integrated packaged hardware and software

o Demonstrate system operation with one or two beta customers

o Expand marketing efforts to generate sales.



University of Massachusetts Lowell

Joey Mead, Professor


This work focuses on the use of electrostatically addressable templates to control polymer assembly, followed by transfer of the pattern to a secondary flexible substrate. In particular, conducting polymers were assembled and transferred to a nonconducting material.

For commercial applications low cost, high volume methods to pattern conducting polymer for the production of miniaturized complex features is needed by industry. Therefore, it is desirable to develop simpler and more rapid processes to pattern conducting polymers. Since electric fields can be used to accelerate the assembly process, it would be ad-vantageous to use electric fields to guide the assembly of conducting polymers directly. There are, however, very few reports about the di-rect assembly of conducting polymers using electrophoretic assembly. Li et al. used electrodes to assemble PANi colloidal particles. In this instance, only a thin PANi film was formed, but the underlying pattern was not reproduced. This is a result of the semiconducting nature of their template. We are able to directly pattern the conducting polymer, provided the template is insulated; otherwise in the deposition process, PANi will be deposited onto the entire template, thereby forming a PANi film, instead of patterned PANi.

For fabrication of actual devices patterning alone may not be sufficient. Thus, in addition to development of the pattern, the ability to transfer the pattern to another substrate will be a required manufacturing step. Methods employing high rate polymer processing technologies, such as injection molding and compression molding to transfer the pattern onto another substrate would be ideal methods for nano-/microfabrication at high efficiency and low cost. Current approaches include the use of double adhesive tape, PU precursors and polydimethylsiloxane (PDMS) to transfer glass beads, polystyrene beads and polypyrrole149. Of great practical importance is the transfer of the patterned assembly onto a flexible polymeric substrate. Our work demonstrates the process of complete pattern transfer from the template to the flexible (polymer) substrate.


Provides the potential to fabricate all-plastic electronics, paper-like displays, and biosensors in a cost-ef-ficient and high rate process. Technology is applicable to a broad range of products.


This technology can be extended to the assembly of any other functional polymer systems, polyelectrolyte, biomolecules, conducting polymers, colloids and other nanoparticles as well.

Defense industry – e.g. Raytheon

Wire and Cable manufacturer’s – e.g. Panduit

Research is presented at a number of companies, research conferences, trade shows, etc.


Joey Mead, Professor


Lowell, MA 01841Phone:978-934-3446Fax: [email protected]




This unique technology can assist companies to utilize this low-cost and rapid reproduction of manufacturing conductive polymer, and provide them with a competitive advantage in the marketplace. This technique does not require expensive equipment or extensive scale-up, the return on investment would be very beneficial for their manufacturing processes.


The University would like to 1) license this technology to companies and develop products based on this manufacturing process or 2) seek entrepreneurs to license the technology as the platform for a start-up. The researchers will be available to assist companies for further development. For licensing opportunity please contact Susu Wong at [email protected].



Vista TherapeuticsPresented by:Spencer Bryant Farr, CEO

Company Overview

Measurement of serum and urinary biomarkers is becoming a routine part of animal research, drug development and safety evaluation, and patient diagnosis and monitoring. Vista Therapeutics, Inc. is commer-cializing nanowire-based biosensors that will allow for real-time, con-tinuous, label-free monitoring of multiple biomarkers simultaneously at femtomolar concentrations. Vista can ‘functionalize’ nanowires to continuously monitor virtually any form of bi-molecular interaction of interest to researchers and clinicians that involves proteins (including antibodies, receptors and enzymes) or nucleic acids. Vista’s NanoSen-sorTM technology allows measurement of distinct types of biomarkers – including gene transcripts, proteins and SNP’s - in the same reaction, simultaneously. Markets for Vista’s NanoSensorTM technology include biomedical research, pre-clinical and clinical drug safety and efficacy, and point-of-care patient monitoring. Vista Founders are Charles Li-eber and Spencer Farr. Vista’s Founders and Principals include highly experienced business people, engineers, scientists, clinicians and in-formatics specialists who boast world-class achievements in each of these areas.


One of the most profound near-term contributions of nanotechnology to biomedicine will be in the form of extremely sensitive biosensors for blood and urinary biomarkers. Nanowires comprised of ‘1-dimensional’ semi-conducting materials have the greatest potential as biosensors because they can easily be incorporated into electronic circuits that allow continuous readout. Nanowires can be ‘functionalized’ to detect virtually any form of bi-molecular interaction that involves proteins (in-cluding antibodies, receptors and enzymes) or nucleic acids. Without the use of chemical or isotopic labels, functionalized nanowires can monitor on a continuous and dynamic basis, antibody-antigen interac-tions, enzyme-substrate interactions, ligand-receptor interactions, as well as gene expression levels.

Through license agreements with Harvard University and Nanosys, Inc., Vista has obtained world-wide exclusive rights via multiple issued patents for most of the important biomedical applications of nanowires. Vista will develop and market dispos-able nanowire-based biosensors that quantify levels of key biomarkers. Through a strategic partnership with the world’s leading designer/manufacturer of continuous biomolecules monitoring equipment, MesoSystems, Inc., Vista will also sell integrated bench-top, bedside and field readers to the pharmaceutical industry, to the biomedical research community, and to critical care providers. Vista intends to market services through alli-ances with large CRO’s by late 2008 and sell integrated NanoSensorTM cartridges and devices by 2009.


Spencer Farr, Ph.D, CEO and Board ChairmanCharles M. Lieber, Ph.D, CSO and Board memberSusanne Roubidoux, Esq, Chief Legal Counsel and Board MemberCharles Call, Ph.D., SAB and Director of EngineeringArmen Tashjian, MD., SAB and Director of Clinical ResearchCedric Francois, MD, Ph.D, SABSam Hicken, Ph.D., Director of Informatics


Vista Therapeutics1701 Old Pecos TrailSanta Fe, NM 87505Phone: 505-988-9190spencer@vistatherapeutics.orgwww.vistatherapeutics.org

Charles Lieber, Ph.D. Professor of Chemistry, CSOHarvard UniversityChemistry DepartmentCambridge, MA 02138Phone: [email protected]




The market opportunities for continuous monitoring incorporate all areas where biomarkers are currently measured, including academic research, drug development, clinical trials and point-of-care patient treat-ment. These annual opportunities are substantial. They Include:

Drug Discovery and Development…………………….……$250 million

Pre-Clinical Safety Assessment. ………………………….. $300 million

Clinical Research and Clinical Trials……………………... $500 million

Point-of-Care Clinical Setting(s)…………………….......…… $2 billion

At-Home Retail Organ Damage Assays. ……………….….$200 million

Military and Bio-weapons………………………………...…..$500 million

Total Opportunity > $3 billion

Vista believes that these markets will increase further in size as technologies such as Vista’s, which provide more accurate and timely biomarker information, become available.

Commercial Opportunities

At least 30% of drug candidates that enter clinical trials fail because of unacceptable toxicity. Continuous measurement of biomarkers of safety in pre-clinical development via Vista’s NanoSensorTM technology will identify drug safety issues earlier and thus save substantial money. Vista will directly market its products to the pharmaceutical industry. It will also market to the clinical trial market through strategic relationships with large CRO’s. These are immediate opportunities for Vista upon product launch.

The current ICU diagnosis/management error rate is at least 18%. Current biomarker measurement technol-ogy which permits only occasional sampling contributes greatly to this high error rate. Vista’s NW-sensors can be functionalized to incorporate all of the biomarkers most relevant to 80% of acute illnesses/injuries in the ICU today. Cost-benefit analysis indicates that if continuous monitoring of 5-8 markers could be provided to approximately 80% of patients admitted to the ED/ICU at an in-hospital cost of around $800 dollars, there would be a net per patient cost savings. Vista’s COGS for its disposable units will be in the low two-digit range. Thus Vista’s technology could save lives, save healthcare-payers’ money, and provide a very hand-some profit. Vista will pursue this huge market opportunity with strategic partnerships with the largest medical device companies.


The only technology besides Vista’s nanowire bio-sensing technology that allows continuous monitoring of biomarkers is surface plasmon resonance (SPR). SPR is significantly less sensitive than Vista’s nanowire technology and lags behind in commercial development. Through a strong portfolio of issued patents, Vista has exclusive rights to functionalized nanowires for detection of health threats. Finally, the inventor of much of Vista’s technology, Dr. Charles Lieber, is a Founder of Vista and will play an active role in its growth and success.


Vista believes it can earn revenues in 2008 and significant revenues in 2009. It can achieve profitability in mid-2010 with staged capitalization totaling approximately $5,000,000. The initial, minimal funding sought is $1,000,000. A second, milestone-based funding would be approximately $1,000,000 within 12 months. Main goals of stage 1 capitalization are to launch service-based components of the business, build prototype bench-top readers, and solicit strategic partnerships with biomarker, pharma and medical device compa-nies.




Exhibitors 37

Additional ExhibitorsHarvard University (tabletop)Robert Benson, Ph.D.

Director of Business DevelopmentOffice of Technology DevelopmentHolyoke Center, Suite 7271350 Massachusetts Avenue, Cambridge, MA 02138Phone: 617-496-3830Fax: 617-495-9568 E-mail: [email protected]

University of Massachusetts Amherst (tabletop)Michael D. Wright

Director of Operations, Planning and DevelopmentCenter for Hierarchical ManufacturingMassNanoTech InstituteUniversity of Massachusetts Amherst322 LGRT, 710 N. Pleasant StreetAmherst, MA 01003-9305(413) 545-1334E-mail: [email protected]

University of Massachusetts Lowell (tabletop)Susu Wong

Commercial Ventures and Intellectual Property (CVIP) 600 Suffolk Street, Second Floor, South Lowell, MA 01854 Phone: 978-934-4722 E-mail: [email protected]

University of Massachusetts Lowell (poster)Sanjeev Manohar

E-mail: [email protected]

Note: Startup Companies in the Pitch Sessions also have Exhibit Tables


3�

Notes


39

Notes


40

Notes

Documents

Conference Co-Chairmttc.org/wp-content/uploads/2014/09/Nano2007_Notebook.pdfemerging nanotechnology and microtechnology industry in Massachusetts: from companies just being formed